Safety results observed in MM-003 were consistent with previous studies of pomalidomide in relapsed/refractory multiple myeloma patients. Full data from the study are being prepared for submission to a future medical meeting for presentation.
“The survival results in this study build on earlier observations of
high response rates for pomalidomide and dexamethasone in multiple
myeloma patients who had been exposed to multiple therapies, including
immunomodulatory agents and proteasome inhibitors,” said Dr.
The MM-003 study compared pomalidomide plus low-dose dexamethasone to high-dose dexamethasone in patients who were relapsed on or refractory to at least two prior therapies that must have included both lenalidomide and bortezomib.
Patients in the pomalidomide arm received 4 mg of oral pomalidomide on days 1-21 of each 28-day cycle, with patients 75 years or younger also receiving 40 mg of oral low-dose dexamethasone and patients older than 75 years receiving 20 mg oral low-dose dexamethasone on days 1, 8, 15 and 22 of each 28-day cycle, until disease progression.
Patients in the comparator arm 75 years and younger received 40 mg oral high-dose dexamethasone on days 1-4, 9-12 and 17-20 of each 28-day cycle, and patients older than 75 years received 20 mg oral high-dose dexamethasone on days 1-4, 9-12 and 17-20 of a 28-day cycle, until disease progression.
The primary endpoint of the study was PFS, with the key secondary endpoint being OS (with alpha control), and other secondary endpoints including safety, response rates and time to progression.
A Marketing Authorisation Application (MAA) for pomalidomide in
combination with dexamethasone was submitted to the EMA in
Additionally, a new drug application (NDA) has been accepted for review
These results are from an investigational study. Pomalidomide is not approved for the treatment of any indication.
Pomalidomide is an IMiDs® compound. Pomalidomide and other IMiDs compounds continue to be evaluated in over 100 clinical trials. The IMiDs compound pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions.
About Multiple Myeloma
Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease remains unknown.
About Celgene International Sàrl
Celgene International Sàrl, located in Boudry, in the
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the
Source: Celgene International Sàrl